Drug Profile
JPH 101
Alternative Names: JPH-101Latest Information Update: 28 May 2022
Price :
$50
*
At a glance
- Originator J-Pharma
- Class Hyperphosphataemia therapies; Small molecules
- Mechanism of Action Phosphate binding modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hyperphosphataemia
Most Recent Events
- 28 May 2022 No recent reports of development identified for preclinical development in Hyperphosphataemia in Japan
- 08 May 2020 JPH 101 is still in preclinical development for Hyperphosphataemia in Japan (J-Pharma pipeline, May 2020)
- 08 May 2020 J-Pharma plans a phase I trial for Hyperphosphataemia (J-Pharma pipeline, May 2020)